What's in Massachusetts Eye and Ear Infirmary's pipeline?

Massachusetts Eye and Ear Infirmary has 14 drugs in our index: 9 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 5 in Phase 1.

Which companies overlap with Massachusetts Eye and Ear Infirmary's portfolio?

Top competitors by shared drug class: Allergan, Bausch & Lomb Incorporated, EMS, Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA, LitePharmTech Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/massachusetts-eye-and-ear-infirmary.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Massachusetts Eye and Ear Infirmary — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Massachusetts Eye and Ear Infirmary pipeline: 9 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9 marketed 0 filed 0 Phase 3 0 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Cyclosporine A 0.05%	Cyclosporine A 0.05%	marketed
OPTI-FREE® RepleniSH®	OPTI-FREE® RepleniSH®	marketed
B+L Advanced Eye Relief Lubricant Drop	B+L Advanced Eye Relief Lubricant Drop	marketed	Artificial tear / Lubricant		Ophthalmology
Loteprednol/tobramycin	Loteprednol/tobramycin	marketed	Corticosteroid/aminoglycoside antibiotic combination	Glucocorticoid receptor (loteprednol); bacterial 30S ribosome (tobramycin)	Ophthalmology
Clear Care®	Clear Care®	marketed	Contact lens care solution / disinfectant		Ophthalmology
ReNu MultiPlus® MultiPurpose Solution	ReNu MultiPlus® MultiPurpose Solution	marketed	Contact lens care solution		Ophthalmology
Atropine 1%	Atropine 1%	marketed	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1-M5, primarily M3 in ocular tissue)	Ophthalmology
Visine Dry Eye Relief eye drops	Visine Dry Eye Relief eye drops	marketed	Artificial tear lubricant		Ophthalmology
Arificial Tear	Arificial Tear	marketed	Ophthalmic lubricant		Ophthalmology

Therapeutic area mix

Ophthalmology · 7

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Allergan · 2 shared drug classes
Bausch & Lomb Incorporated · 1 shared drug class
EMS · 1 shared drug class
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · 1 shared drug class
LitePharmTech Co., Ltd. · 1 shared drug class
National University of Malaysia · 1 shared drug class
Nguyen Viet Giap · 1 shared drug class
Ophthalmic Consultants of Long Island · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Massachusetts Eye and Ear Infirmary:

Cite this brief

Drug Landscape (2026). Massachusetts Eye and Ear Infirmary — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/massachusetts-eye-and-ear-infirmary. Accessed 2026-05-17.